摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲氧基-1-丙胺盐酸盐 | 70807-90-8

中文名称
2-甲氧基-1-丙胺盐酸盐
中文别名
——
英文名称
2-methoxypropan-1-amine hydrochloride
英文别名
2-Methoxy-1-propanamine hydrochloride;2-methoxypropan-1-amine;hydrochloride
2-甲氧基-1-丙胺盐酸盐化学式
CAS
70807-90-8
化学式
C4H11NO*ClH
mdl
MFCD08146657
分子量
125.598
InChiKey
HDXPVDSGCDOOFU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.26
  • 重原子数:
    7
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    35.2
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2922199090
  • 储存条件:
    储存条件:2-8°C,并需保存在惰性气体环境中。

SDS

SDS:5db214d6c2635350c889a7b9f0120194
查看

反应信息

  • 作为反应物:
    描述:
    4-氟-3-硝基苄醇2-甲氧基-1-丙胺盐酸盐N,N-二异丙基乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 1.5h, 以73.7%的产率得到(4-((2-methoxypropyl)amino)-3-nitrophenyl)methanol
    参考文献:
    名称:
    [EN] BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS
    [FR] DÉRIVÉS DE BENZIMIDAZOLE COMME INHIBITEURS DES BROMODOMAINES
    摘要:
    式(I)的化合物及其盐:其中R1、R2、R3、R4在此处定义。已发现式(I)的化合物及其盐能够抑制BET家族的溴结构域蛋白与例如乙酰化赖氨酸残基的结合,因此可能在治疗中发挥作用,例如在治疗自身免疫和炎症性疾病(如类风湿性关节炎)和癌症方面。
    公开号:
    WO2016146738A1
点击查看最新优质反应信息

文献信息

  • HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20180065981A1
    公开(公告)日:2018-03-08
    The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.
    本申请涉及具有特定类型的(氮杂杂环基)甲基取代基的新型噻吩并[2,3-d]嘧啶-2,4-二酮(“噻吩尿嘧啶”)衍生物,以及其制备方法,单独或组合用于治疗和/或预防疾病,以及用于生产用于治疗和/或预防疾病的药物,特别是用于治疗和/或预防肺部和心血管疾病以及癌症的用途。
  • PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
    申请人:Ajinomoto Co., Inc.
    公开号:US20160046592A1
    公开(公告)日:2016-02-18
    An object is to provide a novel compound which has a glycogen synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. Provided is a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: wherein Ar 1 represents any one of the following rings (II) and (III): wherein R 2 represents an alkyl group, and R 3 represents a hydrogen atom or an alkyl group, and R 1 represents any one of the following substituents (IV) and (V):
    提供一种新型化合物,具有糖原合成酶激活能力,但对PPAR受体的激活程度较低且具有高度安全性。提供的化合物由以下一般式(I)或其药学上可接受的盐表示:其中Ar1代表以下环之一(II)和(III):其中R2代表烷基基团,R3代表氢原子或烷基基团,R1代表以下取代基之一(IV)和(V):
  • [EN] AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOHEXANE À SUBSTITUTION AMIDO
    申请人:BAYER PHARMA AG
    公开号:WO2016177658A1
    公开(公告)日:2016-11-10
    The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.
    本发明涉及一般式(I)的酰胺取代环己烷化合物,其中A、R4、R6、R7、R8、R9、R10和R11如本文所定义,涉及制备所述化合物的方法,涉及用于制备所述化合物的中间化合物,涉及包含所述化合物的药物组合物和药物组合物,以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途,特别是肿瘤,作为唯一药剂或与其他活性成分结合使用。
  • AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL
    申请人:SUMITOMO CHEMICAL COMPANY, LIMITED
    公开号:US20170295789A1
    公开(公告)日:2017-10-19
    There is provided a noxious arthropod controlling agent containing an amide compound of formula (I): wherein R 1 represents a C1-C8 chain hydrocarbon group optionally having one or more groups selected from Group A, R 2 represents a hydrogen atom or the like, R 3 represents a hydrogen atom or the like, R 5 and R 6 are the same or different, and independently represent a hydrogen atom or the like, Y represents an oxygen atom or the like, m represents 0, 1, 2, 3, 4, 5, 6 or 7, and Q represents a C1-C8 chain hydrocarbon group optionally having one or more atoms or groups selected from Group D.
    提供了一种含有化合物的有害节肢动物控制剂(I)的公式:其中R1代表一个C1-C8链烃基,可选地具有来自A组的一个或多个基团,R2代表氢原子或类似物,R3代表氢原子或类似物,R5和R6相同或不同,独立地代表氢原子或类似物,Y代表氧原子或类似物,m代表0、1、2、3、4、5、6或7,Q代表一个C1-C8链烃基,可选地具有来自D组的一个或多个原子或基团。
  • [EN] 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2<br/>[FR] DÉRIVÉS DE 1,1-DIOXYDE DE 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE EN TANT QU'INHIBITEURS DE MRGX2
    申请人:SOLENT THERAPEUTICS LLC
    公开号:WO2020223255A1
    公开(公告)日:2020-11-05
    Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R1, R2, R3, R4 and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.
    本公开涉及Formula (1)的化合物及其互变异构体,以及这些化合物或互变异构体的药用可接受盐,其中L、R1、R2、R3、R4和R5在说明书中有定义。本公开还涉及制备Formula (1)化合物的材料和方法,含有这些化合物的药物组合物,以及它们用于治疗与MRGX2相关的疾病、疾患或症状的用途。
查看更多